Cyclacel Pharmaceuticals, Inc. has announced that its majority stockholder has taken action by written consent, resulting in a decision that impacts the company's corporate structure. The decision involves amending the company's Amended and Restated Certificate of Incorporation. This move reflects the company's ongoing strategic adjustments to enhance its operational framework. The action was authorized on May 12, 2025, under the leadership of CEO and Executive Director, Datuk Dr. Doris Wong Sing Ee.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.